Modern Radiopharmaceutical Dosimetry Should Include Robust Biodistribution Reporting.
Radiopharmaceutical dosimetry is an important area of nuclear medicine, and its advances have the potential to affect imaging and radiotherapy development and application protocols. Dosimetry is a computationally intensive, assumption-based process, and not all dosimetry is created equal. In this brief communication, we present biodistribution measurements as a valuable part of radiopharmaceutical dosimetry that is worthy of robust documentation. Biodistribution data are routinely collected in every dosimetry case and are integral to the subsequent dosimetry calculations. Standard documentation of these data may help us understand the value and limitations of our dosimetry estimates, identify errors, resolve discrepancies, and enable the reproducibility of results. We may also recognize that the modern digital landscape provides both opportunity and motivation to usher in the evolution of standards in our field. Ultimately, these steps may improve the current generally poor acceptance of dosimetry procedures by clinicians.